You are leaving the Canadian PNH Network site to go to an external site.
In case you missed it…
New

Anemias and Beyond…Wait Don’t Change the Channel: Investigating these cases may save your patients’ lives!
– Dr. Richard Wells and Dr. Thomas Nevill

To C.A.T.C.H. Paroxysmal Nocturnal Hemoglobinuria: A Shared-care Approach – Dr. Richard Wells

Archived versions of these presentations can be viewed by visiting “Learning Programs”.

Learning Programs

PNH Resources

  • A detailed look at how to C.A.T.C.H. PNH

    The devastating nature of PNH demands early diagnosis, which is essential for improved patient management and prognosis. This document outlines the high-risk patient populations that the International Clinical Cytometry Society (ICCS) recommend be evaluated for PNH. Additional screening information is provided to ensure that PNH can more readily be ruled in or out using high-sensitivity flow cytometry and a comprehensive clinical assessment.

The standardized-flow report represents consensus amongst the experts within the Canadian PNH Network (cPNHn). I would like to thank the Experts within the cPNHn for their thoughtful comments, review and consensus on this project. The cPNHn is especially indebted to the work of Professor D. Robert Sutherland, Professor Department of Medicine University of Toronto who first saw the need, developed the working process to gain consensus, and led this project on behalf of the cPNHn. And, Dr. Graeme Quest, Hematopathologist, and Deputy Director Flow Cytometry, University Health Network who provided guidance, real-world perspective, and clinical expertise in the final design of the flow report template.

Our hope is that by having developed an expertly reviewed and standardized approach for the reporting of PNH results, every single patient who is suffering from this disease can benefit from this report so that he or she receives the best possible care, from diagnosis to therapy as appropriate.

- Dr. Richard Wells, Assistant Professor, Department of Medicine, University of Toronto, Chair, Canadian PNH Network

"This standardized report is going to be very helpful for clinicians and I am sure many technicians as well.

The effort to standardize flow reporting by all labs in Canada is impressive. The entire clinical flow cytometry community could learn from this effort."

- Paul K. Wallace, PhD
2016-2018 President
International Society for Advancement of Cytometry (ISAC)
2016 Advocacy and Program Committee Member
International Clinical Cytometry Society (ICCS)
Director, Flow and Image Cytometry Facility Roswell Park Cancer Institute
Associate Professor of Pathology State University of New York at Buffalo
Professor of Oncology

The following 2 checklists have been developed by the Canadian PNH Network to assist Health Care Providers in the monitoring and management of patients with PNH.

  • Initial evaluation: Patient with newly diagnosed PNH

    This checklist reviews all the tests and evaluations that should ideally be done in patients with a new diagnosis of PNH (i.e., detection of any size of PNH clone by flow cytometry). This checklist allows a Health Care provider to define the clinical management priorities and provide a comprehensive baseline for future follow-up. For newly diagnosed patients already receiving medications that increase meningococcal risk, an additional sub-checklist provides guidance on aspects of prophylaxis that should be addressed.

  • Follow-up of PNH patients after initial workup – routine visit (every 3-4 months) for all patients, regardless of treatment

    This checklist and its sub-checklists outline the tests that should be performed at routine follow-up visits (every 3 to 4 months) and the annual visit for all patients with an established diagnosis of PNH, regardless of whether or not they are receiving treatment. Additional guidance is provided for ongoing monitoring of patients with asymptotic small PNH clones.